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Abstract
Background: Recent reports have suggested a possible involvement of Single-minded homolog 2 (SIM2) in human solid
cancers, including prostate cancer. However, the exact role of SIM2 in cancer in general, and in prostate cancer in particular,
remains largely unknown. This study was designed to elucidate the role of SIM2 in prostate cancer using a shRNA-based
approach in the PC3 prostate cancer cell line.
Methods: Lentiviral shRNAs were used to inhibit SIM2 gene and protein levels in PC3 cells. Quantitative RT-PCR and
branched DNA were performed to evaluate transcript expression. SIM2 protein expression level was measured by western
blot. Profiling of gene expression spanning the whole genome, as well as polar metabolomics of several major metabolic
pathways was performed to identify major pathway dysregulations.
Results: SIM2 gene and protein products were significantly downregulated by lenti-shRNA in PC3 cell line. This low
expression of SIM2 affected gene expression profile, revealing significant changes in major signaling pathways, networks
and functions. In addition, major metabolic pathways were affected.
Conclusion: Taken together, our results suggest an involvement of SIM2 in key traits of prostate tumor cell biology and
might underlie a contribution of this transcription factor to prostate cancer onset and progression.
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Introduction
Single-minded homolog 2 (SIM2) gene is located on the human
chromosome 21q22.2 and is a member of the basic helix-loop-helix
PAS [per-Arnt-Sim] (bHLH-PAS) family of transcription factors
[1,2]. SIM2 was originally thought to contribute to Down’s
syndrome (DS) [3]. As a transcription factor (TF), murine SIM2
(mSIM2) mediates gene expression through CNS midline enhancer
(CME) element with its dimerization partner ARNT via ARNT
carboxy-terminus [4]. The transcription factor c-myb regulates
SIM2 transcription in glioblastoma cells, and a nuclear localization
signal (NLS) mediates nuclear localization of SIM2 [5].
A prior in silico bioinformatics approach using the Cancer
GenomeAnatomy Project (CGAP) database of the National Cancer
Institute (NCI) identified SIM2 as associated with colon, pancreas
and prostate carcinomas, while absent in the corresponding normal
tissues [6]. Twodifferent spliced isoformsof SIM2 transcript,SIM2-
long (SIM2-l) and SIM2-short (SIM2-s), have been reported while
their differential function in humans are not known yet [1]. SIM2-s
was specifically expressed in early stages of colon cancer. Antisense
inhibition of SIM2-s expression by antisense oligos caused growth
inhibition and apoptosis in colon cancer cell line RKO and tumor
growthinnudemiceandalsoinpancreaticcancercelllineCAPAN-
1 [7,8]. Apoptosis was induced by SIM2-s inhibition in the RKO
colon cancer cell line [9]. SIM2-s was also found to have tumor
suppressive activity in breast cancer [10]. The invasion potential of
glioblastoma was decreased significantly by SIM2s inhibition,
consistent with a decrease in the expression of matrix metallopro-
teinase 2 at both mRNA and protein levels [11].
We have previously reported SIM2 as a potential biomarker and
immunotherapy target for human prostate cancer [12]. Although
SIM2-s expression (as measured by immunohistochemistry of
prostatectomy specimens) has been associated with aggressive
histopathology in prostate cancer, and overexpressing ectopic SIM2s
enhanced survival in certain conditions in PC3AR+ cells [13,14], the
functional role of SIM2 gene in prostate cancer cell is largely unknown.
In this study we sought to elucidate the functional role of SIM2
in PCa using a gene silencing approach and characterization of
molecular and functional changes by both gene expression
profiling and metabolomic profiling.
Materials and Methods
Cell lines
The human PC3, LNCaP, VCaP and DU145 cell lines were
purchased from the American Type Culture Collection (ATCC,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28837Manassas, VA) and cultured as per ATCC’s protocol. Benign
PrEC cells, as described in Berger R et al, 2004, were kindly
provided by Dr. W. Hahn at Dana-Farber Cancer Institute,
Boston, MA.
Transduction Particles
The pLKO.1-puro control lentiviral transduction particles,
MISSION luciferase shRNA control lentiviral transduction parti-
cles and MISSION SIM2 shRNA lentiviral transduction particles
were used to infect PC3 cell line (Sigma-Aldrich, Saint Louis, MO).
Sample selection, RNA purification and reverse
transcription
Ten benign and fourteen tumor radical prostatectomy tissue
samples were obtained and total RNAs were processed as
described in our previous work [12]. Cell line total RNA was
isolated using TRIzol reagent (Invitrogen Corporation, Carlsbad,
CA) according to the manufacturer’s instructions. Purified RNA
was quantified by NanoDrop ND-1000 Spectrophotometer
(NanoDrop, Wilmington, DE). 500 ng of each cell total RNA
was reverse transcribed into cDNA using oligo dT and superscript
III reverse transcriptase (Invitrogen Corporation, Carlsbad, CA)
under the manufacturer’s instructions.
Gene expression microarrays and analysis
250 ng total RNA was amplified using Ambion’s MessageAmp II
mRNA Amplification kit. Biotin-UTP was incorporated during the
overnight in vitro transcription step according to the manufacturer’s
protocol. Gene expression was assessed using Affymetrix’s (Santa
Clara, CA) GeneChip U133 array (Plus 2.0 chip) arrays
representing the whole human genome transcripts. 15 mg cRNA
was fragmented and hybridized to arrays’ according to the
manufacturer’s protocols as described previously [15]. The quality
of scanned arrays images were determined on the basis of
background values, percent present calls, scaling factors, and 39-59
ratio of b-actin and GAPDH using the BioConductor R packages.
The signal value for each transcript was summarized using PM-only
based signal modeling algorithm described in dchip. The PM only
based modeling based algorithm yields less number of false positives
as compared to the PM-MM model. In this way, the signal value
corresponds to the absolute level of expression of a transcript [16].
These normalized and modeled signal values for each transcript
were used for further high level bioinformatics analysis. During the
calculationofmodelbased expressionsignal values, arrayandprobe
outliers are interrogated and images spike are treated as signal
outliers. The outlier detection was carried out using dchip outlier
detection algorithm. A chip is considered as an outlier if the probe,
single or array outlier percentage exceeds a default threshold of 5%.
When comparing two groups of samples to identify genes enriched
in a given phenotype, if 90% lower confidence bound (LCB) of the
fold change (FC) between the two groups was above 1.2, the
corresponding gene was considered to be differentially expressed.
LCB is a stringent estimate of FC and has been shown to be the
better ranking statistic [17] It has been suggested that a criterion of
selecting genes that have a LCB above 1.2 most likely corresponds
to genes withan ‘‘actual’’ foldchange of at least 2 ingene expression
[18]. Data were extracted from CEL files and normalized using
RMAexpress (http://rmaexpress.bmbolstad.com/). Data were
analyzed using MeV software (http://www.tm4.org/mev/).
Cell signaling pathway analysis
The Ingenuity Pathways Analysis (Ingenuity SystemsH, http://
www.ingenuity.com) applications were used to generate networks
and assess statistically relevant biofunctions, canonical pathways
and networks associated with the differentially expressed gene
profiles extracted from the transcriptome data.
Branched DNA and quantitative Real-Time PCR (qRT-PCR)
Branched DNA was performed to evaluate the SIM2s and
SIM2L gene expression in the human prostate total RNA samples
and normalized by 2 control genes ALSA1 and HPRT
(QuantiGene 2.0 Reagent System, Affymetrix Inc, Fremont,
CA). For quantitative RT-PCR, 1 ml cDNA was used for each
well RT-PCR reactions. Samples were performed in triplicates.
Taqman universal PCR Master Mix (Applied Biosystems, Foster
City, CA) was used for two-step real-time RT-PCR analysis
on Applied Biosystems 7900HT Prism instrument. Taqman real
time PCR primers for GAPDH (4310884E) and SIM2L
(hs00231925_m1) were purchased from Applied Biosystems
(Foster City, CA). Taqman real time PCR primers for SIM2s
were designed by our group and purchased from Biosearch
Technologies (Novato, CA). SIM2s forward primer: 59-gtgccaagct
acgaaggtg-39; SIM2s reverse primer: 59-acttagaagcagaaagaggg-
caag-39; probe: TCAGGTCTGCTCGTGGGGAAGGTG. Ex-
pression value of SIM2s or SIM2L in a given sample was
normalized to the corresponding expression of GAPDH. The
2
–DDCt method was used to calculate relative expression of SIM2
gene as described previously [19,20].
Lentiviral transduction and stable cell line selection
1.6 X 10
4 PC3 cells were plated in 96 well plate and incubated
for 20 hours. Medium was removed and 110 ul of fresh medium
containing hexadimethrine bromide to a final concentration of 8
ug/ml were added. Lentiviral particles were added to appropriate
wells at 5 MOI (multiplicity of Infection) and incubated overnight.
Fresh medium was then added and cells cultured for 2 days,
followed by a 10–12 days culture with puromycin (2 ng/ml) added
every 3 days.
Transient transduction was achieved over a 3-day incubation.
Western blot
Cells were washed twice with PBS twice before they were
harvested by scraping. Cell lysates were prepared in cell lysis buffer
(50 mmol/L Tris-HCl pH 8.0, 20 mM EDTA, 1% SDS, and 100
mM NaCl) containing an enzyme inhibitor mixture tablet (Roche
Molecular Biochemicals, Indianapolis, IN) and PMSF (Sigma-
Aldrich, Saint Louis, MO). Protein concentration was determined
using BCA protein assay kit (Thermo Scientific, Rockford, IL). A
total of 20–50 mg of protein extract was fractionated by SDS-
PAGE and transferred to a polyvinylidene difluoride membrane
(Immobilon-P; Millipore). The membrane was blocked with TBS-
T (0.1% Tween 20 in PBS) containing 3% dry milk and incubated
with SIM2s primary antibody (Santa Cruz, sc-8715, isoform
NM_009586) overnight at 4uC. After three washes with TBS-T,
the membrane was incubated with HRP-conjugated secondary Ab
for 1 h and then washed with 0.05% Tween 20 in PBS. The
immune complexes were detected by ECL methods (Thermo
Scientific, Rockford, IL).
Metabolite profiling using Targeted Liquid-
Chromatography Tandem Mass Spectrometry (LC/MS/
MS)
10
6 cells exponentially growing in basal media with dialyzed
serum were harvested in 3 mL 80% v/v HPLC grade methanol at
dry ice temperatures. Fresh media was added 24 hours and 2
hours prior to the extraction. Insoluble material in lysates was
SIM2 and Prostate Cancer
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28837Table 1. Clinical information and SIM2 gene expression of 10 normal and 14 tumor prostatectomy evaluated by branched DNA
technique.*
Case number
Tumor = 1
normal = 0
Gleason
score
PSA level
(ng/ml)
Sim2s mRNA
expression **
Sim2L mRNA
expression ** Sim2s/Sim2L ratio
315 0 N/A 7.6 0.0025 0.0024 1.041667
318 0 N/A 8.4 0.0057 0.008 0.7125
322 0 N/A 6.5 0.0182 0.0197 0.923858
334 0 N/A 5 0.0368 0.0645 0.570543
91 0 N/A 5 0.0215 0.0321 0.669782
20 0 N/A 7.2 0.01 0.0233 0.429185
149 0 N/A 7.1 0.0045 0.0057 0.789474
516 0 N/A 13.5 0.029 0.0379 0.765172
524 0 N/A 11.5 0.0338 0.0805 0.419876
544 0 N/A 7.8 0.0241 0.1094 0.220293
411 1 3+4=7 0.4 0.1449 0.2734 0.529993
417 1 3+4=7 4.2 0.2041 0.2281 0.894783
471 1 3+4=7 26.7 0.0414 0.0375 1.104
474 1 3+3=6 5.2 0.1711 0.2817 0.607384
478 1 3+4=7 4.4 0.0543 0.0921 0.589577
482 1 3+4=7 8.3 0.0513 0.1066 0.481238
523 1 3+4=7 8.7 0.2476 0.3987 0.621018
539 1 3+3=6 0.7 0.1956 0.5371 0.364178
545 1 3+3=6 3 0.1005 0.1996 0.503507
547 1 3+3=6 0.4 0.0824 0.134 0.614925
548 1 4+3=7 5.8 0.0606 0.1403 0.431932
303 1 N/A 6.4 0.0631 0.1084 0.582103
14 1 N/A 1.6 0.1812 0.2005 0.903741
125 1 4+3=7 18 0.0333 0.0494 0.674089
*Prostatectomy samples were from Hershey Tissue Bank at Beth Israel Deaconess Medical Center, Boston.
**mRNA expression values were normalized by ALSA1 and HPRT genes by branched DNA technique.
doi:10.1371/journal.pone.0028837.t001
Figure 1. SIM2 expression in human prostatectomy, prostate normal and cancer cell lines. Quantitative Expression of SIM2 short isoform
(A) and SIM2 long isoform (B) were evaluated by branched DNA technique in 10 normal and 14 human cancer prostatectomy specimens. Data were
quantified using ALSA1 and HPRT as the normalizers. (C) Quantification of SIM2 short and long isoforms’ expression in human prostate normal and
cancer cell lines by real time RT-PCR. Data were quantified by the DDCT method and normalized to GAPDH. Column in white represents SIM2 short
isoform and column in gray represents SIM2 long isoform. (D) Western blot were performed in prostate normal and cancer cell lines for SIM2s.
doi:10.1371/journal.pone.0028837.g001
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supernatant (metabolite content) was evaporated using a refriger-
ated SpeedVac to a pellet. Samples were re-suspended using 20mL
HPLC grade water for mass spectrometry analysis. 10mL were
injected and analyzed using a 5500 QTRAP triple quadrupole
mass spectrometer (AB/Sciex) coupled to a Prominence UFLC
HPLC system (Shimadzu ) via selected reaction monitoring (SRM)
of a total of 255 endogenous water soluble metabolites for steady-
Figure 2. SIM2 expression in PC3 cells is downregulated by shRNA. Real time RT-PCR was performed in triplicates (A) and protein expression
was evaluated by western blot (B). Control 1: Luciferase shRNA vector, Control 2: PLKO vector. sh48, sh49, sh50, sh50, sh51 and sh52: vectors
expressing shRNAs targeting SIM2 gene at different sites. Column with ‘‘*’’ represents significant downregulation of SIM2 gene expression by shRNA
comparing to both of control 1 and control 2 (P , 0.05).
doi:10.1371/journal.pone.0028837.g002
Figure 3. Heat map and cell signaling analysis for the dysregulated genes in SIM2
low comparing to control PC3 cells. A. Control A: PC3
luciferase shRNA; Control B: PC3 PLKO vector; SIM2 C: SIM2 sh48; SIM2 D: SIM2 sh51. Gene expressions were either up or down greater than 2 fold in
the SIM2
low were listed. B. Top dysregulated signaling pathways in SIM2
low PC3 cells. C. Top dysregulated cell functions in SIM2
low PC3 cells.
doi:10.1371/journal.pone.0028837.g003
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positive and negative ion mode for a total of 298 SRM transitions.
ESI voltage was +4900V in positive ion mode and –4500V in
negative ion mode. The dwell time was 5 ms per SRM transition
and the total cycle time was 2.09 seconds. Approximately 8–10
data points were acquired per detected metabolite. Samples were
delivered to the MS via normal phase chromatography using a 2.0
mm i.d x 15 cm Luna NH2 HILIC column (Phenomenex) at 285
mL/min. Gradients were run starting from 85% buffer B (HPLC
grade acetonitrile) to 42% B from 0–5 minutes; 42% B to 0% B
from 5–16 minutes; 0% B was held from 16–24 minutes; 0% B to
85% B from 24–25 minutes; 85% B was held for 7 minutes to re-
equilibrate the column. Buffer A was comprised of 20 mM
ammonium hydroxide/20 mM ammonium acetate (pH=9.0) in
95:5 water:acetonitrile. Peak areas from the total ion current for
each metabolite SRM transition were integrated using Multi-
Quant v1.1 software (AB/Sciex).
Measurements were performed in triplicates and data were
normalized per cell number. Only metabolites that were determined
in all 6 sampleswerekept and analyzed usingMetaboAnalyst[21,22].
Statistical analysis
Gene expression array data were analyzed as described under
Materials and Methods. Based upon our earlier work [12], we
tested for SIM2 upregulation in tumors versus controls with a
one-sided t-test and compared against a p-value threshold of
0.05.
Quantitative Real-Time PCR (qRT-PCR). Validation of
differentially expressed genes was performed by qRT-PCR. 200 ng
of high quality RNA samples were reverse transcribed to first
strand cDNA and 1 ml cDNA was used for each well RT-PCR
reaction. Samples were performed in triplicates. SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA) was used
for two-step real-time RT-PCR analysis on Applied Biosystems
7900HT Prism instrument. PCR primers’ sequences for targeted
genes are shown in Table S3. The sequences for GAPDH:
GAPDH-F (59-TGCACCACCAACTGCTTAGC -39) and GAP-
DH-R (59-GGCATGGACTGTGGTCATGAG -39). Expression
value of the targeted gene in a given sample was normalized to the
corresponding expression of GAPDH. The 2
–DDCt method was
used to calculate relative expression of the targeted genes.
Figure 4. Top one network dysregulated in SIM2
low. This network contained 16 focus genes with a score of 29. Different shapes of the node
represent different groups of the focus genes. The intensity of the node color indicated the degree of the up (red) and down (green) gene expression
level. The top functions of this network are cellular movement, immune cell trafficking, organismal injury and abnormalities.
doi:10.1371/journal.pone.0028837.g004
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SIM2 gene is differentially expressed in prostate normal
and cancer prostatectomy and cell lines
We have evaluated SIM2 gene expression in a total of 24
normal and tumor prostatectomy samples shown in table 1.
Because SIM2 gene exists in two isoforms, SIM2 short (SIM2s)
and SIM2 long (SIM2L), we confirmed the expression of both
isoforms in RNA extracted from prostatectomy using branched
DNA technique (Fig. 1A & 1B). SIM2s and SIM2L showed
significant overexpression in tumor samples when compared to
benign samples, with p , 0.000003 and p , 0.00005, respectively.
However, the ratio of SIM2s to SIM2L expression was no
difference between benign and tumor (table 1, T-test with p =
0.85). The SIM2s and SIM2L expression were 7.03 and 6.95 times
higher respectively in the tumors comparing the means of the two
groups after a log adjustment to assure normality and constant
variance within each group. Expression of SIM2s and SIM2L was
also evaluated in four human prostate cancer cell lines, PC3,
LNCaP, DU145 and VCaP, and in the normal prostate epithelial
cell line PrEC. Both SIM2s and SIM2L isoforms were highly
expressed in VCaP cells, while there was a moderate expression
level in PC3 cells and very low expression in DU145, LNCaP, and
PrEC cells (Fig. 1C). Because there are only a few available
antibodies to SIM2, we have only been able to clearly identify the
short isoform of SIM2 (SIM2s) in cellular protein extracts by
western blot. This scarcity of antibodies complicated our task of
studying the function of SIM2 long isoform. The SIM2s protein
expression level was consistent with its gene expression in prostate
normal and cancer cell lines. (Fig. 1D).
Silencing SIM2 expression in PC3 cells
To achieve the highest downregulation of SIM2 expression
using lentiviral shRNA, we have selected the PC3 cell line as a
model. PC3 cells were transduced with five different SIM2 shRNA
expression vectors, four of which (shRNA48, shRNA49, shRNA50
and shRNA51) showed significant inhibitory effect compared to
control shRNAs. Over 80% silencing of gene expression was
achieved using shRNA51 (Fig. 2A&B). Two control cell lines were
generated using either a vector stably expressing shRNA targeting
luciferase or an empty vector. A similar inhibitory pattern was
observed for SIM2L gene expression in these stably infected PC3
cell lines. Similarly, efficient transient silencing of SIM2S and
SIM2L was achieved in PC3 (Figure S1).
Impact of SIM2 silencing on gene expression profile in
PC3 cells
Despite its suspected role in cancer, very little is known about
the contribution of the transcription factor SIM2 to the regulation
Figure 5. Validation of selected genes from stable transfectant by qRT-PCR. qRT-PCR validation of mRNA expression levels of individual
genes was performed by two-step real-time RT-PCR analysis on Applied Biosystems 7900HT Prism instrument. *, P,.05; **, P,.01; ***, P,.001.
Measurements were performed in triplicates and data presented as Mean 6 SD.
doi:10.1371/journal.pone.0028837.g005
SIM2 and Prostate Cancer
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28837of gene expression [23]. We therefore examined the effects of
downregulation of SIM2 in prostate cancer cells. To this end, the
shRNA which yielded the highest silencing rate of SIM2, i.e.
shRNA51, was selected. PC3 cells treated with shRNA51 were
compared to a control shRNA (shRNAc).
Gene expression profiles of PC3 SIM2
low and control PC3 cell
lines were evaluated using Affymetrix GeneChip U133 array (Plus
2.0 chip) consisting of .52,000 transcripts from whole human
genome transcripts. Figure 1 is a heat map showing the gene
dysregulation after knocking down the expression of SIM2 in PC3
cells. The expression of a large number of transcripts exhibited a
change of at least 2-fold (Figure 3A and Table S4). Pathway
analysis revealed that many highly differentially expressed
transcripts represent genes that belong to known signaling
pathways, such as the PTEN and PI3K/AKT signaling pathways
(Figure 3B), whose involvement in tumorigenesis is well docu-
mented [24,25]. Specific genes involved in each signaling pathway
are shown in Table S1. Among those genes, CCL5, MAPK1, P38,
DDR1 and ERK played a central role in the pathway network
(Figure 4). The genes in this network have been involved in cell
death, metabolism, cellular development, and tumor antigen
presentation. More genes involved in the highest score networks
are shown in Table S2. Further analysis showed that a number of
important biological functions are dysregulated following SIM2
silencing (Figure 3C). Interestingly, several cell functions related to
metabolism, such as drug metabolism and metabolic disease, are
among the top ranked functions.
Validation by RT-PCR of a group of differentially expressed
genes (Table S3) partially confirmed our in silico analysis of stable
and transient transfectant PC3 cells (Figures 5 & 6).
Figure 6. Validation of selected genes from transient transfectant by qRT-PCR. qRT-PCR validation of mRNA expression levels of individual
genes was performed by two-step real-time RT-PCR analysis on Applied Biosystems 7900HT Prism instrument. *, P,.05; **, P,.01; ***, P,.001.
Measurements were performed in triplicates and data presented as Mean 6 SD.
doi:10.1371/journal.pone.0028837.g006
Table 2. Top dysregulated metabolic pathways in Sim2
low
PC3 cells.
Pathway Name
Total number of
Metabolites Hits
Purine Metabolism 92 11
Pyrimidine metabolism 60 6
Glycolysis or
Gluconeogenesis
31 3
Thiamine metabolism 24 2
Pyruvate metabolism 32 2
Metabolites were measured using mass spectrometry and data were analyzed
using MetaboAnalyst software.
doi:10.1371/journal.pone.0028837.t002
SIM2 and Prostate Cancer
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low cells showed major alterations in their
metabolic profile
We sought to determine whether gene expression changes result
in significant shifts in metabolic pathways in PC3 SIM2
low cells.
This was addressed by measuring 255 polar metabolites using
targeted mass spectrometry (LC/MS/MS). Comparison of the
metabolic profile of control cells to shRNA-SIM2-treated cells
showed significant changes in several metabolic pathways and the
production of 39 metabolites (Tables 2&3). The purine metabo-
lism pathway was the top one dysregulated pathway with 11
metabolites significantly up- or down-regulated levels out of total
92 metabolites in this pathway in SIM2 silencing PC3 cells.
Pyrimidine metabolism pathway listed as the second dysregulated
pathway with 6 out of total of 60 metabolites with significant
changed levels (Table 2, Fig. 7). The significant alterations to the
nucleic acid metabolism may indicate its important role in the
prostate cancer development.
Discussion
In our previous biomarker identification efforts, we have
identified SIM2 as a potential biomarker for PCa. Thanks to its
overexpression in prostate tumors and its highly restricted
expression in humans, we proposed to use SIM2 as an
immunotherapy target and were able to identify 5 HLA-A2.1,
SIM2-derived immunogenic epitopes [12]. In the present study we
attempted to characterize the role of SIM2 in prostate cancer
using a short hairpin RNA-induced gene silencing approach in
PC3 cells as a model. We focused on profiling both the
transcriptome and metabolome in SIM2
low and normal PC3 cells,
and evaluated the impact of SIM2 silencing on cell signaling and
function.
The SIM2s isoform has been reported to be expressed in colon,
pancreas, and prostate tumors while absent in the corresponding
benign tissues [8]. We found that SIM2 genes are detectable in all
these prostate cancer cells by real time PCR. However the
expression levels in DU145 and LNCaP are relatively lower than
other prostate cancer cells while PC3 cells express moderate level
of SIM2 genes which are consistent with other report [14].
The whole spectrum of regulation of gene expression by the
transcription factor SIM2 is still poorly defined. The level of
regulation could be reflected by the differential expression of about
200 genes as revealed through gene expression profiling of PC3
SIM2
low cells. Other groups have reported specific genes that are
regulated by SIM2. The bHLH/PAS transcription factor single
minded 2s was reported to promote mammary gland lactogenic
differentiation by regulation of Csn2 expression [26]. SIM2
regulates the expression of MMP-2 and TIMP-2, which drive its
role in glioblastoma cells [11]. SIM2s represses BNIP3, a pro-
apoptotic gene, through its hypoxic response element in PC3 cells
[14]. Our gene expression profile in PC3 SIM2
low cells showed
significant change in PTEN, PI3K/AKT and Toll-like receptor
(TLR) signaling pathways which are involved largely in the tumor
progression. PTEN negatively controls the PI3K signaling
pathway for cell growth and survival by dephosphorylating the 3
position of phosphoinositides [24,25]. TLR regulates cell prolif-
eration and survival and central signaling molecules mitogen-
activated protein kinase (MAPK) and PI3K play key roles [27].
Our data show that inhibition of Sim2 gene in PC3 cells affects
expression of several genes encoding proteins that are organized in
a network around p38MAPK. These proteins, which include
CCL5, MAPKs, ERK and DDR1 (Figure 4), have been reported
to be involved in tumor development. The chemokine CCL5 has
been reported to be expressed by prostate cells and affect their
growth and survival. Following activation of MAPKs p38 and
ERK1/2 in LNCaP cells, the expression of CCL5 increases,
resulting in enhanced cell proliferation [28,29]. PC3 cell
proliferation and invasion were also significantly suppressed after
DDR1 knockdown by siRNA [30,31].
Our RT-PCR data revealed discrepancies between transient
and stable silencing of SIM2 in PC3 cells. This may be a result of
1) the presence of two isoforms of SIM2 that are silenced to
Table 3. List of dysregulated metabolites in Sim2
low PC3 cells.
Metabolite P value*
UTP 0.00021736
CTP 0.000266674
Thiamine-phosphate 0.00027101
CDP 0.00027427
ATP 0.00032043
GDP 0.00047402
2-ketohaxanoic acid 0.00099085
dGTP 0.0011366
Adenosine 0.0025014
allantoate 0.0031712
4-Pyridoxic acid 0.0032341
Hydroxyphenylacetic acid 0.004154
IMP 0.0046357
Inosine 0.0052766
xanthosine 0.0056235
N-carbamoyl-L-aspartate 0.0057818
CDP-choline 0.0067616
lactate 0.007935
GTP 0.0084853
dCTP 0.011521
dATP 0.011737
Geranyl-PP 0.014616
Thiamine pyrophosphate 0.017058
dihydroxy-acetone-phosphate 0.017355
AMP 0.018114
Sn-glycerol-3-phosphate 0.019883
3-phosphoglycerate 0.021186
UDP 0.023169
dAMP 0.023309
Guanine 0.025068
Glucose-6-phosphate 0.027664
Fructose-6-phosphate 0.035608
Hexose-phosphate 0.036721
dTMP 0.044375
Guanosine 5-diphosphate, 3-diphosphate 0.046342
2-Isopropylmalic acid 0.047328
GMP 0.04827
hydroxyproline 0.049448
Metabolites were quantitated using mass spectrometry and data were analyzed
using MetaboAnalyst software.
*P,0.05.
doi:10.1371/journal.pone.0028837.t003
SIM2 and Prostate Cancer
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expression of other genes either directly or indirectly.
Function analysis also revealed that three functions related to
cell metabolism had been dysregulated in the PC3 SIM2
low cells.
This suggested that SIM2 might have metabolic consequences. We
have evaluated the production by PC3 cells of 255 metabolites that
encompass a large number of human metabolic pathways. Of
these, data were obtained for 239 metabolites. Our analysis
revealed significant changes in metabolites that constitute key
pathways, such as the purine and pyrimidine pathways.
Suppression of SIM2 short isoform (SIM2s) by antisense
oligonucleotides reduced tumor growth in colon cancer cells and
induced CAPAN-1 pancreatic cell death through apoptosis
[7,8,9]. SIM2s was also reported to be an aggressive prostate
cancer biomarker since SIM2s protein was associated with
increased preoperative serum prostate specific antigen (PSA), high
histological grade, invasive tumor growth and increased tumor cell
proliferation [13]. A recent study showed that SIIM2s may
attenuate cell death processes through BNIP3 repression in
PC3AR+ cells. However, knockdown of SIM2s in breast cancer
MCF-7 cells increased tumorigenesis and thus showed tumor
suppressor activity [32,33]. Most of the previous studies focused on
the SIM2s by either intruding or knockdown of SIM2s, we are
lacking of the data clarifying the functional role of SIM2 protein
including both of its isoforms. Our study reported a combined role
of both isoforms of the SIM2 implicated in the prostate cancer cell.
Distinguishing the roles of SIM2s and SIM2L may have more
profound meaning to understand the functional role of SIM2 in
prostate cancer progression, which is our next step to uncover
more significance of this gene.
Supporting Information
Figure S1 Transient silencing of SIM2s and SIM2L expression
in PC3 cells. PC3 cells were transduced with either a control (Ctrl)
or shRNA51 (sh51) and cultured in the presence of puromycin for
3 days. Real time RT-PCR was performed in triplicates to
evaluate gene expression of SIM2 s (Upper Panel) and SIM2L
(Lower Panel).
(TIF)
Table S1 The top Dysregulated Signaling Pathways in SIM2
low
cells. Top dysregulated canonical pathways were identified
through analysis of differentially expressed gene data, using
Ingenuity Pathway Analysis package.
(DOC)
Table S2 The Molecules in the Highest Score Networks in
SIM2
low cells. Data representing differentially expressed genes
were submitted to Ingenuity Pathway Analysis package and high
score networks were identified.
(DOC)
Table S3 List of primers used for RT-PCR quantitation of
expression of of selected genes. The primers were designed using
Pimer3 program: http://frodo.wi.mit.edu/primer3/.
(DOC)
Table S4 Gene expressions that were either up- or down-
regulated greater than 2 fold in the SIM2
low.
(XLSX)
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